The main goal of this study is to employ a novel proteomic approach to identify predictive tumor biomarkers that will increase the efficacy of insulin-like growth factor (IGF1R) targeted therapy in epithelial ovarian cancer. It is expected that these predictive biomarkers will be applied to increase the response rate in selected groups of patients.
Study Type
OBSERVATIONAL
Enrollment
20
Hillel Yaffe Medical Center
Hadera, Israel
Responsive to IGF1R therapy
Mean tumor volume will be calculated and growth inhibition will be reported as the percentage decrease of tumor volume compared with the control.
Time frame: One year
Proteomic Signature of IGF1R Responsive Tumors
Mass Spectrometry will be used to compare IGF1R responsive and non-responsive tumors to identify the proteins associated with sensitivity to IGF1R therapy.
Time frame: One year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.